Abstract
Keywords
Targeted therapy Receptor tyrosine kinase inhibitor Breast cancer Schiff base Cell cycle block Antiproliferative
Introduction
Cancer is one of the most lethal diseases in the world. According to the latest GLOBOCAN report, a project of the International Agency for Research on Cancer (IARC), more than 18 million new cases of cancer and over 9 million cancer-related deaths have been registered in 2018 worldwide (2). There have been considerable improvements in several available pharmacological tools for the management of cancer; however, these therapeutic strategies very often suffer from severe limitations including inadequate efficacy, systemic toxicity, and development of drug resistance(Ya). In this regard, the discovery of novel anticancer agents with improved efficacy and toxicity profiles is a necessity and also a major challenge for the scientific community(T).
Phenanthrene-based derivatives are well established as antitumor agents (4, 5) showing antiproliferative effects in different cancers including breast cancer (6), non-small cell lung cancer (7, 8), as well as several others (6) (Figure 1). Phenanthroindolizidine and phenanthroquinolizidine derivatives from the alkaloid chemical class of compounds have also been reported as potent anti-tumor agents (9, 10). Phenanthrene derivatives have been reported to exert their anticancer effect by interference with DNA synthesis and intercalation with DNA base pairs (4, 5), interference with the cancer cell cycle (6) and (W,S)activation of apoptotic pathways (6-8, 11).
On the other hand, several hetero-fused 1,2,4-triazine derivatives have shown significant antitumor action against different cancer types (12). These compounds have been reported to induce their effect by several mechanisms including apoptosis induction and cell cycle perturbation in cancer cells (13).
In recent years, molecularly targeted small molecule agents have achieved considerable success in treatment of different types of cancer (14). Receptor tyrosine kinases (RTKs) are frequently found to be altered and overexpressed in several tumor types and they have been linked with certain hallmarks of cancer including proliferation, invasion as well as metastasis (15-17). RTKs are currently considered crucial targets to design small-molecule inhibitors with anticancer potential (18, 19). MET proto-oncogene (c-Met) is one of the well-studied RTKs and several compounds with inhibitory potential against this target are being developed to fight against cancer (20-23). Among several studied chemical scaffolds, the hetero-fused 1,2,4-triazine derivatives have also been reported to inhibit c-Met kinase in previous studies (24-27).
In continuation of our interest in the discovery of novel anticancer agents (28, 29), we focused on structural modifications of previously reported antiproliferative agents including phenanthrene (Figure 1, compounds 1 and 2) (4, 30) and 1,2,4-triazine (Figure 1, compound 3 and 4) (13, 31) as innovative backbones to design potent antiproliferative agents. In addition, according to previous reports, hydrazone linkers (Figure 1, compounds 5 and 6) (32, 33) have also been widely presented as promising cytotoxic structures. Based on these studies, twelve novel derivatives of phenanthrotriazine bearing imine linkers of appropriate aryl pendants were synthesized. The effect of synthesized compounds on human cancer cell proliferation, cell cycle, and induction of apoptosis was investigated. Docking analysis was used to study compounds’ interactions with the c-Met receptor active site.
Experimental
Chemistry
Melting points were determined with a MEL-TEMP model 1202D. FT-IR spectra were recorded with a Bruker Tensor 27 spectrometer as KBR disks. The MS spectra were recorded using Agilent 7000-3Q mass spectrometer at an electron impact mode with an ionization voltage of 70 eV. 1H-NMR and 13C-NMR spectra were recorded with Bruker Spectrospin Avance 300 and 75 MHz spectrometers. CDCl3 and DMSO were used as solvents, while TMS was utilized as an internal standard for chemical characterizations. All chemical shifts were reported as δ (ppm) and coupling constants (J) are given in Hz. Thin-layer chromatography was performed with glass-backed plates (20 × 20 cm2, 500 μ) using silica gel (Merk Kieselgel 60 HF254, Art. 7739). The chemical reagents used for the synthesis were purchased from Merck and Sigma-Aldrich.
Synthesis of phenanthro(9,10-e)(1,2,4)triazine 3-thiol (3)
To a solution of Phenanthrene 9, 10 dione (1) (10 mmol) and acetic acid (40 mL), thiosemicarbazide (2) (20 mmol) was added and refluxed for 4 h. The reaction progression was monitored using TLC. The precipitated product was filtered and washed with enough amounts of cold water and ethanol mixture. Orange solid; Yield: 95%; mp: 122-124 °C; 1H-NMR (300 MHz, CDCl3): δH 14.65 ppm (s, 1H, NH), 8.55 (m, 2H, Ar-H), 8.15 (m, 5H, Ar-H), 7.55 (m, 9H, Ar-H), 6.72 (s, 1H, SH); IR (KBr, cm -1) υ max: 3413 (-NH-), 3145 (ArCH), 1596 (Ar N=N), 1500 (-C=N-), 1481 (Ar C=C); MS (EI) m/z (%): 263 (M+, 40), 235 (89), 176 (100).
Synthesis of 3-(methylthio)phenanthro(9, 10-e)(1,2,4)triazine (5)
Phenanthrotriazine thiol (3) (10 mmol) was added to the mixture of NaOH (460 mg, 11.5 mmol) in warm ethanol (50 mL) then the excess amount of methyl iodide (4) (15 mmol, 1 mL) was added after the temperature was decreased. The reaction mixture was stirred at room temperature for 3 h. The reaction progress was monitored using TLC. The resulting yellow suspension was filtered through a filtration paper and then washed with enough amounts of cold ethanol. Yellow solid; Yield: 78%; mp: 157-160 °C; 1H-NMR (300 MHz, CDCl3): δH 14.65 ppm (s, 1H, NH), 8.55 (m, 2H, Ar H), 8.15 (m, 5H,Ar H), 7.55 (m, 9H, Ar H), 6.72 (s, 1H, SH); IR (KBr, cm -1) υ max:2927 (ArCH), 1605 (Ar N=N), 1503 (-C=N-), 1482 (Ar C=C); MS (EI) m/z (%): 263 (M+, 40), 235 (89), 176 (100).
3-(2-benzylidene hydrazinyl)phenanthro(9, 10-e)(1,2,4)triazine(7)
Methyl thiol (5) (2 mmol) was dissolved in 2-propanol and refluxed. Excess amounts of hydrazine hydrate (6) (5 mL) were added and the mixture was refluxed overnight and the reaction progression was monitored using TLC. The resulting yellow suspension was filtered through a filtration paper and then washed with enough amounts of cold water.
Yellow solid; Yield: 77%; IR (KBr, cm -1) υ max: 3444 (-NH-), 3039 (ArCH), 1556 (Ar N=N), 1523 (-C=N-), 1447 (Ar C=C); MS (EI) m/z (%): 261 (M+, 57), 286 (79), 190 (100).
General procedure for the synthesis of hydrazones (9a-l)
Hydrazine (7) (0.5 mmol) was dissolved in warm ethanol (20 mL). The appropriate aryl aldehyde (8) (0.5 mmol) was added and the reaction mixture was refluxed for 3 h and the reaction progression was monitored using TLC. The resulting yellow suspension was filtered through a filtration paper and then washed with enough amounts of cold ethanol.
3-(2-benzylidenehydrazinyl)phenanthro [9,10-e][1,2,4]triazine (9a)
Yellow solid; Yield: 73%; mp: 286-290 °C; 1H-NMR (300 MHz, DMSO): δH9.14-9.17 (m, 2H, Ar H),8.83-8.86 (m, 2H, Ar H), 8.40 (s, 1H, =CH), 7.96-7.99 (d, J = 9 Hz, 1H, Ar H),7.81-7.89 (m, 5H, Ar H), 7.44-7.54 (m, 3H, Ar H); IR (KBr, cm -1) υ max: 3419 (-NH-), 2983 (ArCH), 1588 (Ar N=N), 1529 (-C=N-), 1447 (Ar C=C); MS (EI) m/z (%): 349 (M+, 24), 272 (28), 218 (100), 190 (96).
3-(2-(2-methoxybenzylidene)hydrazinyl)phenanthro[9,10-e][1,2,4]triazine (9b)
Yellow solid; Yield: 76%; mp: 252-254 °C; 1H-NMR (300 MHz, DMSO): δH9.12-9.16 (m, 2H, Ar H),8.77-8.82 (m, 2H, Ar H), 8.75 (s, 1H, =CH),8.04-8.07 (d, J = 9Hz, 1H, Ar H),7.93-7.97 (m, 1H, Ar H), 7.78-7.83 (m, 3H, Ar H), 7.40-7.45 (t, J = 9Hz, 1H, ArH), 7.07-7.15 (m, 2H, Ar H), 3.90 (s, 3H, CH3); IR (KBr, cm -1) υ max: 3445 (-NH-), 2977 (ArCH), 1584 (Ar N=N), 1522 (-C=N-), 1447 (Ar C=C); MS (EI) m/z (%): 379 (M+,29), 272 (14), 246 (37), 218 (100), 190 (76).
3-(2-(4-methoxybenzylidene)hydrazinyl)phenanthro[9,10-e][1,2,4]triazine (9c)
Yellow solid; Yield: 76%; mp: 288-292 °C; 1H-NMR (300 MHz, DMSO): δH9.14-9.16 (m, 2H, Ar H),8.83-8.85 (m, 2H, Ar H), 8.34 (s, 1H, =CH),7.94-7.99 (m, 1H, Ar H),7.76-7.83 (m, 5H, Ar H), 7.06-7.08 (d, J = 6 Hz, 2H, Ar H), 3.83 (s, 3H, CH3); IR (KBr, cm -1) υ max: 3445 (-NH-), 2989 (ArCH), 1611 (Ar N=N), 1526 (-C=N-), 1430(Ar C=C); MS (EI) m/z (%): 379 (M+, 12), 245 (27), 218 (100), 190 (55).
2-((2-(phenanthro[9,10-e][1,2,4]triazin-3-yl)hydrazono)methyl)phenol (9d)
Yellow solid; Yield: 61%; mp: 328-332 °C; 1H-NMR (300 MHz, DMSO): δH9.09-9.15 (m, 2H, Ar H),8.84-8.87 (m, 2H, Ar H), 8.56 (s, 1H, =CH),7.97-8.02 (t, J = 9 Hz, 1H, Ar H),7.81-7.91 (m, 3H, Ar H), 7.51-7.57 (d, J = 6 Hz, 1H, Ar H), 7.30-7.36 (t, J = 7.5 Hz, 1H, Ar H), 6.97-7.05 (m, 2H, Ar H); IR (KBr, cm -1) υ max: 2966 (ArCH), 1585 (Ar N=N), 1525 (-C=N-), 1430 (Ar C=C); MS (EI) m/z (%): 365 (M+, 45), 218 (100), 190 (92).
3-((2-(phenanthro[9,10-e][1,2,4]triazin-3-yl)hydrazono)methyl)phenol (9e)
Yellow solid; Yield: 64%; mp: 219-223 °C; 1H-NMR (300 MHz, DMSO): δH9.06-9.14 (m, 3H, Ar H),8.78 (s, 1H, =CH), 8.71-8.76 (m, 2H, Ar H),7.90-7.94 (t, J = 7.2 Hz, 2H, Ar H),7.72-7.80 (m, 5H, Ar H), 4.63 (s, 1H, NH); IR (KBr, cm -1) υ max: 3445 (-NH-), 3047 (ArCH), 1556 (Ar N=N), ~1530 (-C=N-), 1447 (Ar C=C); MS (EI) m/z (%): 365 (M+, 16), 286 (27), 272 (31), 218 (85), 190 (100).
3-((2-(phenanthro[9,10-e][1,2,4]triazin-3-yl)hydrazono)methyl)benzene-1,2-diol (9f)
Yellow solid; Yield: 57%; mp: 329-333 °C; 1H-NMR (300 MHz, DMSO): δH9.11-9.19 (m, 2H, Ar H),8.80-8.87 (m, 2H, Ar H), 8.52 (s, 1H, =CH),7.98-8.03 (t, J = 7.2 Hz, 1H, Ar H),7.81-7.90 (m, 3H, Ar H), 6.97-7.00 (d, J = 6 Hz, 1H, Ar H), 6.88-6.90 (d, J = 6 Hz, 1H, Ar H), 6.76-6.81 (t, J = 9 Hz, 1H, Ar H); IR (KBr, cm -1) υ max: 3495 (-NH-), 2851 (ArCH), 1596 (Ar N=N), 1525 (-C=N-), 1470 (Ar C=C); MS (EI) m/z (%): 381 (M+, 80), 364 (21), 218 (99), 190 (100).
3-(2-(2-nitrobenzylidene)hydrazinyl)phenanthro[9,10-e][1,2,4]triazine (9g)
Yellow solid; Yield: 70%; mp: 225-229 °C; 1H-NMR (300 MHz, DMSO): δH8.98-9.15 (m, 3H, Ar H),8.75 (s, 1H, =CH), 8.68-8.72 (m, 2H, Ar H),7.87-7.97 (m, 2H, Ar H),7.72-7.84 (m, 5H, Ar H), 4.61 (s, 1H, NH); IR (KBr, cm -1) υ max: 3445 (-NH-), 3038 (ArCH), 1643 (-NO2), 1556 (Ar N=N), 1524 (-C=N-), 1447 (Ar C=C); MS (EI) m/z (%): 395 (M+, <10), 261 (100), 233 (18), 190 (82).
3-(2-(3-nitrobenzylidene)hydrazinyl)phenanthro[9,10-e][1,2,4]triazine (9h)
Yellow solid; Yield: 57%; mp: 216-219 °C; 1H-NMR (300 MHz, DMSO): δH9.05-9.19 (m, 3H, Ar H),8.77 (s, 1H, =CH), 8.70-8.74 (m, 2H, Ar H),7.86-7.97 (t, J = 6.9 Hz, 2H, Ar H),7.74-7.83 (m, 5H, Ar H), 4.62 (s, 1H, NH); IR (KBr, cm -1) υ max: 3444 (-NH-), 3038 (ArCH), 1644 (NO2), 1556 (Ar N=N), 1523 (-C=N-), 1447 (Ar C=C); MS (EI) m/z (%): 261 (94), 190 (100), 175 (44), 205(21), 233(17).
3-(2-(4-nitrobenzylidene)hydrazinyl)phenanthro[9,10-e][1,2,4]triazine (9i)
Yellow solid; Yield: 58%; mp: 240-244 °C; 1H-NMR (300 MHz, DMSO): δH9.05-9.12 (m, 3H, Ar H),8.77 (s, 1H, =CH), 8.71-8.74 (m, 2H, Ar H), 7.89-7.94 (t, J = 7.2 Hz, 2H, Ar H),7.74-7.79 (m, 5H, Ar H), 4.63 (s,1H, NH); IR (KBr, cm -1) υ max: 3444 (-NH-), 3046 (ArCH), 1556 (Ar N=N), 1523 (-C=N-), 1447 (Ar C=C); MS (EI) m/z (%): 394 (M+, 25), 272 (34), 218 (79), 190 (100).
4-((2-(phenanthro[9,10-e][1,2,4]triazin-3-yl)hydrazono)methyl)benzonitrile (9j)
Yellow solid; Yield: 54%; mp: 231-234 °C; 1H-NMR (300 MHz, DMSO): δH9.03-9.11 (m, 3H, Ar H),8.76 (s, 1H, =CH), 8.71-8.75 (m, 2H, Ar H),7.87-7.93 (t, J = 9Hz, 2H, Ar H),7.72-7.78 (m, 5H, Ar H), 4.63 (s, 1H, NH); IR (KBr, cm -1) υ max: 3444 (-NH-), 3035 (ArCH), 2226 (CN), 1556 (Ar N=N), 1523 (-C=N-), 1447 (Ar C=C); MS (EI) m/z (%): 374 (M+, 28), 272 (35), 218 (81), 190 (100).
3-(2-((1H-pyrrol-2-yl)methylene)hydr -zinyl)phenanthro[9,10-e][1,2,4]triazine (9k)
Yellow solid; Yield: 63%; mp: 210-214 °C; 1H-NMR (300 MHz, DMSO): δH9.02-9.12 (m, 3H, Ar H),8.76 (s, 1H, =CH), 8.71-8.73 (m, 2H, Ar H),7.88-7.96 (t, J = 6.9 Hz, 1H, Ar H),7.74-7.85 (m, 5H, Ar H); IR (KBr, cm -1) υ max:3439 (-NH-), 2917 (ArCH), 1556 (Ar N=N), 1524 (-C=N-), 1447 (ArC=C); MS (EI) m/z (%): 338 (M+, <10), 261 (100), 190 (84), 176 (38).
3-(2-(thiophene-2-ylmethylene)hydraz-inyl)phenanthro[9,10-e][1,2,4]triazine (9l)
Yellow solid; Yield: 40%; mp: 228-231 °C; 1H-NMR (300 MHz, DMSO): δH9.07-9.11 (m, 3H, Ar H),8.75 (s, 1H, =CH), 8.66-8.73 (m, 2H, Ar H),7.87-7.92 (t, J = 8.1 Hz, 1H, Ar H),7.67-7.83 (m, 5H, Ar H), 4.61 (s, 1H, NH); IR (KBr, cm -1) υ max: 3445 (-NH-), 1556 (Ar N=N), 1524 (-C=N-), 1447 (Ar C=C); MS (EI) m/z (%): 355 (M+, 14), 246 (31), 218 (100), 190 (81).
Evaluation of the antiproliferative effect
Fetal bovine serum (FBS), phosphate-buffered saline (PBS), RPMI-1640, and trypsin were obtained from Biosera (Ringmer, UK). Penicillin/streptomycin and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) were from Sigma-Aldrich (Saint Louis, MO, USA) and Invitrogen (San Diego, CA, USA), respectively. Dimethyl sulfoxide and doxorubicin were purchased from Merck (Darmstadt, Germany) and EBEWE Pharma (Unterach, Austria), respectively. The cells were acquired from Iranian Biological Resource Center, Tehran, Iran (HT-29 (human colorectal adenocarcinoma), MCF-7 (human breast adenocarcinoma) and Vero (African green monkey kidney) cells) or National Cell Bank of Iran, Pasteur Institute, Tehran, Iran (MOLT-4 (lymphoblastic leukemia) cells).
MTT reduction assay was employed to assess the viability of cancer cells after being treated with synthesized derivatives as previously described (34). The cells were plated in flat-bottom 96-well microplates, at densities of 3 × 104 cells/mL (100 μL in each well) and then incubated overnight at 37 °C. Three to four different concentrations of synthesized derivatives (in the range of 1 to 100 μM) were placed in triplicate wells and the plates were incubated for 72 h at 37 °C. The concentration of DMSO did not exceed 0.25% in each well. At the end of the incubation time, 80 μL of the media in each well was replaced with the same amount of growth medium without phenol red containing 0.5 mg/mL of MTT. Cells were further incubated at 37 °C for 4 h and then 80 μL of the solution of each well was removed. The addition of DMSO (200μL) to each well solubilized the formazan crystals formed inside the viable cells after 1-hour incubation followed by 30-minute shaking. The optical absorbance of the final solution was determined at 570 nm using a Bio-Tek multimode plate reader (Synergy HTX). The cell viability was calculated compared to untreated control cells by comparison of absorbance measurements. CurveExpert software (version 1.34 for Windows) was used to determine the IC50 value for each compound. To confirm the results, every experiment was repeated 3 to 5 times.
Cell Cycle Analysis
Alterations of the cell cycle were determined by the propidium iodide (PI)-RNase flow cytometric method (35). MCF-7 cells were used to determine the percentage of cells in each phase of the cell cycle. In 6-well plates, 2 × 105 cells were seeded in each well and incubated at 37 °C for 48 h. Afterward, they were treated for 48 h with derivatives 9g, 9j, 9k and 9l at 10 and 25 μM. The cells were then collected after trypsinization, washed twice with PBS, and fixed by 5 mL ethanol 70% for at least 24 h at -20 °C. After fixation, MCF-7 cells were washed with PBS two times and stained with PI 20 µg/mL and RNase 200 µg/mL for 30 min in the dark at room temperature. A FACS Calibur flow cytometer (BD Biosciences) was used for the assays and 20,000 events were analyzed. The number of cells distributed in sub-G1, G0/G1, S, and G2/M were determined by CellQuest software (BD, USA).
Hoechst 33258 staining
Hoechst 33258 was used as a DNA stain to detect apoptosis in cells. MCF-7 cells were seeded in a 6-well plate at a density of 5 × 104 cells/mL (2 mL per well) and incubated for 24 h. The whole medium was removed and different concentrations of test compounds 9g, 9j, 9k, and 9l diluted in 2 mL medium were placed in the different wells and incubated for 72 h. Afterward, the medium was removed again, 1 mL of 4% cold freshly prepared paraformaldehyde (PFA) was added, and cells were incubated for 20 min at room temperature. The cells were then washed 2 times with 1 ml PBS and incubated with 1 mL Hoechst 33258 2.5 µg/mL for 30 min in the dark at room temperature (36, 37). In the end, the cells were washed with 1 mL PBS and imaged with a fluorescence microscope.
Docking analysis
The two most potent compounds (9k and 9l) were prepared using MarvinSketch 18.20.0 and geometry optimization was carried out by the steepest descent algorithm with MOPAC. The crystal structure of c-Met kinase receptor in complex with selective a c-Met inhibitor was obtained from the RCSB Protein Data Bank (PDB code 3ZZE). The molecular docking study was done with a GOLD software package using the GoldScore and ChemPLP scoring functions and default settings. The active site of protein was defined for the protein residues within 8 Å of the cognate ligand that accompanied the downloaded protein complexes. The cognate ligand was docked inside the 3ZZE to validate the docking algorithm using both scoring functions. Re-docking of the cognate ligand resulted in RMSD values of 0.854 Å and 1.01Å, for GoldScore and ChemPLP, respectively. Thus, the score value of the interactions between the ligands and c-Met kinase receptors with PDB code 3ZZE was calculated in terms of the GoldScore fitness function. The GoldScore fitness value for cognate ligand was calculated as 32.50. The molecular models of the docked compounds were visualized in the BIOVIA Discovery Studio software package and Pymol Software 1.7.4.4 Edu.
Results and Discussion
Chemistry
The synthesis route of the compounds 9a-l is depicted in Scheme 1. Firstly, the starting material phenanthrene 9, 10 dione 1 was treated with thiosemicarbazide 2 in acetic acid (40 mL) conditions to give phenanthro(9,10-e)(1,2,4)triazine 3-thiol 3 with a relatively high yield (95%). Subsequently, methylation of the thiol 3 through a nucleophilic substitution reaction was accomplished using methyl iodide 4 to afford 3- methylthio)phenanthrotriazine derivative 5 (yield 78%). The hydrazinolysis of the methylthiol intermediate 5 was done via a nucleophilic substitution reaction in the presence of hydrazine hydrate to form the hydrazine product 7. In the final step, several aryl aldehydes were attached to the hydrazine phenanthrotriazine 7 intermediate via an imine linkage to give the corresponding phenanthrotriazine hydrazones products 9a-l in 40–76% yields. The 1H NMR spectra of all compounds were in good agreement with the structures, appearing at comparable chemical shifts with those reported for other hydrazones with different substituted (31).
Evaluation of the anticancer activity
The antiproliferative effect of newly synthesized compounds was assessed against three human cancer cell lines including HT-29 (colorectal adenocarcinoma), MCF-7 (breast adenocarcinoma) and MOLT-4 (lymphoblastic leukemia) cells as well as Vero (African green monkey kidney) cells, a normal cell line frequently used as non-cancer reference cells by several investigators (38-40). Doxorubicin and cisplatin were also tested as standard cytotoxic agents (Table 1).
Compounds 9a and 9f did not lower cell viability below 50% at the highest tested concentrations (25 µM). Two analogs including 9c and 9d were not tested due to the very low solubility in aqueous media. The remaining 8 compounds among 12 tested derivatives, displayed considerable antiproliferative effects against the cancer cell lines with IC50 values ranging 7.6-20.1, 4.7-17.7 and 1.7-7.8 µM, against HT-29, MCF-7 and MOLT-4 cells, respectively.
The highest antiproliferative effects against MCF-7 and MOLT-4 cells were observed by compound 9k containing pyrrole moiety with IC50 values of 4.5 ± 0.16 and 1.7 ± 0.2 µM, respectively, while the highest potency against HT-29 cells was demonstrated by 9i bearing para nitrophenyl group with an IC50 value of 7.6 ± 0.8 µM. Derivative 9k, showed negligible effect against normal Vero cells with an IC50 value of 95.4 ± 12.4 µM, while derivative 9i was almost equally effective against non-cancer cells with an IC50 value of 7.4 ± 1.4 µM.
In a previous report, the antiproliferative effect of a series of phenanthro[9,10-d]imidazole/oxazole and acenaphtho[1,2-d]imidazole derivatives were evaluated against the NCI-60 panel of cancer cell lines and it was similarly shown that these derivative possess antiproliferative activity against different cancer cell lines including breast and colon cancer as well as leukemia, among others (4).
Our findings showed that overall the compounds had similar activities against 3 tested cell lines. Considering the influence of different substitutions on the antiproliferative activity, the following structure-activity relationships can be presented:
The presence of heterocyclic rings may enhance the anticancer effect of the derivative against all three cell lines, as shown for derivatives 9k and 9l containing pyrrole and thiophene moieties, respectively. The effect of pyrrole substitution in compound 9k was particularly interesting, because it conferred a high anticancer effect, while it caused an almost entire sparing of normal cells.
The presence of CN (as in 9j) and NO2 (as in 9g, 9h and 9i) groups on the phenyl ring lead to the enhancement of the antiproliferative activity against cancer cells probably by the establishment of H-bonding and polar interactions. Among these derivatives, 9h was less effective against non-cancer cells. Derivatives 9g and 9j had higher IC50 values against normal cells compared to breast cancer (MCF-7) and leukemia (MOLT-4) cells, but not compared to colon cancer (HT-29) cells.
Introduction of OCH3 moiety (as in 9b) seemed to lower antiproliferative effect against cancer cells, increasing the IC50 value especially against MCF-7 (15.2 ± 3.1 µM).
Compounds 9g, 9j, 9k and 9l possessing high activities, each one containing different moieties including nitrophenyl, cyanophenyl, pyrrole and thiophene, respectively, were selected for further analysis of cell cycle alterations, apoptosis, and interaction with the c-Met receptor.
Cell cycle analysis
The influence of compounds 9g, 9j, 9k and 9l on the MCF-7 cancer cell cycle progression was investigated to gain more information on the mechanism of action of derivatives. The cells were treated with 10 and 25 µM concentrations of each derivative for 48 h. Percentages of cells in sub-G1, G0/G1, S and G2/M phases of the cell cycle after being treated with the test compounds are shown in Table 2 and representative histograms are displayed in Figure 2. All four compounds significantly enhanced the number of cells in the G0/G1, while they decreased the percentage of cells in S and G2/M at both concentrations of 10 and 25 µM. Derivatives 9g, 9k and 9l at 25 µM also increased the cells in the sub-G1 phase, which is an index of apoptosis induction in cancer cells.
A recent study has shown the antiproliferative effect of a series of fifteen 1,2,3-triazolo-phenanthrene derivatives against various cancer cell lines including prostate, breast, lung, gastric, cervical cancer cells. The effect of one of the most potent compounds with an IC50 value of 1.5 ± 0.09 µM against DU-145 prostate cancer cells was examined on the alterations of cell cycle distribution in these cells and it was found that indeed this derivative considerably increased the percentage of cells in G0/G1 phase, while decreasing the cells in S and G2/M phase (30). Another previous report has similarly shown that aminopyridazinone derivatives could also arrest SH-SY5Y neuroblastoma cells in G0/G1 phase (41).
Hoechst 33258 staining
Apoptosis induction in MCF-7 cells upon 72-hour treatment with compounds 9g, 9j, 9k and 9l was measured by Hoechst 33258 staining (Figure 3). Hoechst 33258 is a stain that by specifically binding to DNA, can characterize the morphological changes of apoptotic cells, including nuclear shrinkage and fragmentation. Cells treated with all 4 select derivatives, especially 9k and 9l at 25 µM showed signs of apoptosis. Consistent with the moderate increase in the sub-G1 phase of the cell cycle, also here we observed that only at higher concentrations and after being exposed for a longer time (72 h) mild to moderate levels of apoptosis could be observed.
Computational studies and binding mode analysis
Docking studies of all the synthesized derivatives were performed by GOLD software to investigate their binding modes. It has been shown that hetero-fused 1,2,4-triazine derivatives inhibit Met kinase and exert antiproliferative effects in breast, lung and liver cancer cells (24, 25). Previous studies have also reported that c-Met kinase inhibitors may block the cell cycle progression in G0/G1 phase and also induce apoptosis at higher doses and extended periods of incubation time (42, 43).
The obtained GOLD Score value and the key interactions of all compounds with the c-Met receptor (PDB code: 3ZZE) are presented in Table 3. It is generally expected that a c-Met inhibitor must form several hydrogen bonds and hydrophobic interactions with the kinase domain of the receptor based on the type of inhibitors: type I inhibitors occupy the ATP site, while type II inhibitors occupy the adjacent allosteric site in addition to the ATP-binding pocket (44, 45). For the selected most active compounds 9k and 9l, complete models of the interaction in 3D and 2D views of c-Met kinase domain are displayed in Figures 4A-4C. Accordingly, we found an H-bond interaction between the backbone of phenanthrotriazine and Asn1209. Furthermore, different interactions including VDW and Pi-interactions between heteroaromatic moiety of pendants and the 4 residues Arg1208, Arg1166, Asp1164, and Asp1231 were clearly observed. Comparing the best poses found for derivatives 9k and 9l, it was revealed that they might mimic type I kinase inhibitors, since the amino acid residues around the bound type I ligands are generally Asp1164, Ile1084, Gly1085 (44).
It has been previously reported that 1,2,4-triazine derivatives may have an inhibitory potential against c-Met. Based on the results obtained by El-Wakil and colleagues, an optimization on 1,2,4-triazine scaffold and conjugation with mercaptopurine led to the identification of a potent c-Met kinase inhibitor derivative, which showed higher activity compared to reference compounds foretinib and BMS-777607 against A549, HT-29 and MKN-45 cancer cells lines. The binding mode analysis revealed similar key interactions by hydrogen bonds (Met 1160, Lys 1110, and Asp 1222) with other lead compounds from these series (27).
Antiproliferative activities of synthesized derivatives against cancer cells assessed by MTT reduction assay
Effect of synthesized derivatives on distribution of MCF-7 cells in different phases of cell cycle assessed by propidium iodide/RNase flow cytometric assay
| Sample | Sub G1 | G0/G1 | S | G2/M |
|---|---|---|---|---|
| Control | 0.93 ± 0.1 | 61.33 ± 1.0 | 14.35 ± 0.9 | 23.14 ± 1.0 |
| 9g (10 µM) | 1.35 ± 0.3 | 69.25 ± 2.1* | 8.79 ± 1.3* | 18.58 ± 2.2 |
| 9g (25 µM) | 1.82 ± 0.3* | 74.76 ± 4.9* | 7.58 ± 1.9* | 13.97 ± 3.3* |
| 9j (10 µM) | 1.08 ± 0.2 | 71.40 ± 2.2* | 9.59 ± 2.0* | 17.95 ± 3.0 |
| 9j (25 µM) | 1.30 ± 0.4 | 73.10 ± 3.0* | 8.09 ± 2.0* | 17.51 ± 2.6* |
| 9k (10 µM) | 1.31 ± 0.1 | 77.30 ± 2.8* | 4.63 ± 0.7* | 16.63 ± 2.5* |
| 9k (25 µM) | 1.69 ± 0.4* | 77.42 ± 3.7* | 4.68 ± 1.2* | 16.13 ± 2.9* |
| 9l (10 µM) | 1.32 ± 0.3 | 73.76 ± 0.6* | 6.28 ± 1.0* | 18.50 ± 1.7* |
| 9l (25 µM) | 1.56 ± 0.3* | 72.07 ± 0.9* | 6.75 ± 0.9* | 19.43 ± 0.8* |
Results of the computational study of synthesized derivatives docked into the c-Met protein active site (PDB code 3ZZE).
| Compound | Gold Score | Interaction of the backbone with c-Met | Interaction of the pendant with c-Met |
|---|---|---|---|
| 9a | 59.66 | H bond: Asn1209, Arg1208 | Pi-anion:Asp1164, Asp1231 |
| 9b | 59.59 | H bond: Asn1209, Arg1208 | Pi-anion:Asp1164, Asp1231 |
| 9c | 62.71 | H bond: Asn1209 | H bond: Asp1164, Arg1166 |
| 9d | 54.33 | H bond: Asn1209 | H bond: Asp1164 |
| 9e | 57.14 | H bond: Met1160, pro1158 | - |
| 9f | 58.51 | H bond: Asn1209 | H bond: Arg1170, Arg1166 |
| 9g | 51.15 | H bond: Asn1209 | Pi-anion:Asp1164, Asp1231 |
| 9h | 50.29 | - | Pi-pi T shaped: Tyr1230 |
| 9i | 55.89 | Pi staked:Tyr1230 | H bond: Met1160 |
| 9j | 57.73 | H bond: Asn1209 | Hydrophobic: Arg1208, Arg1166 |
| 9k | 61.53 | H bond: Asn1209 | Pi-anion: Asp1164, Asp1231 |
| 9l | 50.37 | Pi-pi T shaped: Tyr1230 | Hydrophobic: Arg1208 |
| Crizotinib | 60.59 | Met1160, Asp1222, Tyr1230, Arg1208 | |
Conclusion
We designed a 4-step reaction protocol to synthesize novel chemicals with phenanthrene triazole scaffold under conveniently available conditions. Most synthesized compounds showed in vitro antiproliferative effects against colorectal cancer, breast cancer, and leukemia cells as determined by the MTT assay. Four compounds including 9g, 9j, 9k and 9l possessing high antiproliferative activities, containing 2-nitrophenyl, 4- cyanophenyl, pyrrole and thiophene moieties, respectively, were selected for further studies. Compound 9K showed an almost negligible effect on non-cancer cells. Derivatives 9g and 9j had higher IC50 values against normal cells compared to MCF-7 and MOLT-4 cells, but not compared to HT-29 cells. Analysis of cell cycle alterations revealed that the derivatives significantly increased the percentage of cells in the G0/G1 phase of the cell cycle and also the sub-G1 phase at higher concentrations in MCF-7 cells. Apoptosis assay revealed that derivatives induced moderate levels of apoptosis in the same cells. These effects on the cell cycle and induction of apoptosis at higher doses and longer incubations times was consistent with other reports on the biological effects of RTK inhibitors including c-Met blocking agents. Based on these observations and also the structural similarity of the synthesized derivatives with previously reported c-Met inhibitors, we hypothesized that these compounds may interact with this RTK and examined the interaction of active compounds with the active site of c-Met. The findings of the docking study showed that most of the compounds, especially the ones with higher potencies, showed reasonable interactions with the c-Met kinase domain.
Overall, the findings of this study show that compounds with phenanthrotriazine structure possess considerable anticancer effects and this activity may be due to their inhibitory potential against the c-Met receptor. Hence, these compounds, especially the ones with low activity against normal cells, represent promising agents as molecularly targeted small molecules to fight against cancer.
Acknowledgements
References
-
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Cancer J. Clin. 2019;69:7-34.
-
2.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 2018;68:394-424.
-
3.
A Baudino T. Targeted cancer therapy: the next generation of cancer treatment. Curr. drug discov. technol. 2015;12:3-20. [PubMed ID: 26033233].
-
4.
Singh I, Rani R, Luxami V, Paul K. Synthesis of 5-(4-(1H-phenanthro [9, 10-d] imidazol-2-yl) benzylidene) thiazolidine-2, 4-dione as promising DNA and serum albumin-binding agents and evaluation of antitumor activity. Eur. J. Med. Chem. 2019;166:267-80. [PubMed ID: 30721822].
-
5.
Wei L, Brossi A, Kendall R, Bastow KF, Morris-Natschke SL, Shi Q, Lee K-H. Antitumor agents 251: Synthesis, cytotoxic evaluation, and structure–activity relationship studies of phenanthrene-based tylophorine derivatives (PBTs) as a new class of antitumor agents. Biorg. Med. Chem. 2006;14:6560-9.
-
6.
Kamal A, Sreekanth K, Kumar PP, Shankaraiah N, Balakishan G, Ramaiah MJ, Pushpavalli S, Ray P, Bhadra MP. Synthesis and potential cytotoxic activity of new phenanthrylphenol-pyrrolobenzodiazepines. Eur. J. Med. Chem. 2010;45:2173-81. [PubMed ID: 20171761].
-
7.
Liao HF, Pan CH, Chou PY, Chen YF, Wu TS, Sheu MJ, Wu CH. Toxicological effects of NCKU-21, a phenanthrene derivative, on cell growth and migration of A549 and CL1-5 human lung adenocarcinoma cells. PLoS One. 2017:12.
-
8.
Kuo CT, Hsu MJ, Chen BC, Chen CC, Teng CM, Pan SL, Lin CH. Denbinobin induces apoptosis in human lung adenocarcinoma cells via Akt inactivation, Bad activation, and mitochondrial dysfunction. Toxicol. Lett. 2008;177:48-58. [PubMed ID: 18262737].
-
9.
Wang Z, Wu M, Wang Y, Li Z, Wang L, Han G, Chen F, Liu Y, Wang K, Zhang A. Synthesis and SAR studies of phenanthroindolizidine and phenanthroquinolizidine alkaloids as potent anti-tumor agents. Eur. J. Med. Chem. 2012;51:250-8. [PubMed ID: 22417638].
-
10.
Song JI, Kang YJ, Yong H-Y, Kim YC, Moon A. Denbinobin, a phenanthrene from Dendrobium nobile, inhibits invasion and induces apoptosis in SNU-484 human gastric cancer cells. Oncol. Rep. 2012;27:813-8. [PubMed ID: 22089965].
-
11.
Patel A, Sharp SY, Hall K, Lewis W, Stevens MF, Workman P, Moody CJ. Fused imidazoles as potential chemical scaffolds for inhibition of heat shock protein 70 and induction of apoptosis Synthesis and biological evaluation of phenanthro [9, 10-d] imidazoles and imidazo [4, 5-f][1, 10] phenanthrolines. Org. Biomol. Chem. 2016;14:3889-905. [PubMed ID: 27035072].
-
12.
Cascioferro S, Parrino B, Spano V, Carbone A, Montalbano A, Barraja P, Diana P, Cirrincione G. An overview on the recent developments of 1, 2, 4-triazine derivatives as anticancer compounds. Eur. J. Med. Chem. 2017;142:328-75. [PubMed ID: 28851503].
-
13.
Fu DJ, Song J, Hou YH, Zhao RH, Li JH, Mao RW, Yang JJ, Li P, Zi XL, Li ZH. Discovery of 5, 6-diaryl-1, 2, 4-triazines hybrids as potential apoptosis inducers. Eur. J. Med. Chem. 2017;138:1076-88. [PubMed ID: 28763643].
-
14.
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553:446-54. [PubMed ID: 29364287].
-
15.
Regad T. Targeting RTK signaling pathways in cancer. Cancers. 2015;7:1758-84. [PubMed ID: 26404379].
-
16.
Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang W, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhao W, Shen H, Laird PW, Way GP, Grenne CS, Liang H, xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick KF, Meyerson M, VanAllen EM, Cherniack AD, Ciriello G, Sander C, Schultz N. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018;173:321-37. [PubMed ID: 29625050].
-
17.
Moosavi F, Giovannetti E, Saso L, Firuzi O. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. Crit. Rev. Clin. Lab. Sci. 2019;56:533-66. [PubMed ID: 31512514].
-
18.
Takeuchi K, Ito F. Receptor tyrosine kinases and targeted cancer therapeutics. Biol. Pharm. Bull. 2011;34:1774-80. [PubMed ID: 22130229].
-
19.
Damghani T, Moosavi F, Khoshneviszadeh M, Mortazavi M, Pirhadi S, Kayani Z, Saso L, Edraki N, Firuzi O. Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met. Sci. Rep. 2021;11:3644. [PubMed ID: 33574356].
-
20.
Cui JJ. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress. J. Med. Chem. 2014;57:4427-53. [PubMed ID: 24320965].
-
21.
Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klumpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hesel C, Borgman-Hagey AE, Schwab G, Kelley RK. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 2018;379:54-63. [PubMed ID: 29972759].
-
22.
Firuzi O, Che PP, El Hassouni B, Buijs M, Coppola S, Lohr M, Funel N, Heuchel R, Carnevale I, Schmidt T, Mantini G, Avan A, Saso L, Peters GJ, Giovannetti E. Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. Cancers. 2019;11:638.
-
23.
Moosavi F, Giovannetti E, Peters GJ, Firuzi O. Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer. Crit. Rev. Oncol. Hematol. 2021;160:103234. [PubMed ID: 33497758].
-
24.
Dadashpour S, Küçükkılınç TT, Ayazgök B, Hosseinimehr SJ, Chippindale AM, Foroumadi A, Irannejad H. Discovery of novel 1, 2, 4-triazolo-1, 2, 4-triazines with thiomethylpyridine hinge binders as potent c-Met kinase inhibitors. Future Med. Chem. 2019;11:1119-36. [PubMed ID: 31280674].
-
25.
Schroeder GM, Chen X-T, Williams DK, Nirschl DS, Cai Z-W, Wei D, Tokarski JS, An Y, Sack J, Chen Z. Identification of pyrrolo [2, 1-f][1, 2, 4] triazine-based inhibitors of Met kinase. Bioorg. Med. Chem. Lett. 2008;18:1945-51. [PubMed ID: 18289854].
-
26.
El-Wakil MH, Ashour HM, Saudi MN, Hassan AM, Labouta IM. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors. Bioorg. Chem. 2017;73:154-69. [PubMed ID: 28715754].
-
27.
El-Wakil MH, Ashour HM, Saudi MN, Hassan AM, Labouta IM. Design, synthesis and molecular modeling studies of new series of antitumor 1, 2, 4-triazines with potential c-Met kinase inhibitory activity. Bioorg. Chem. 2018;76:154-65. [PubMed ID: 29175587].
-
28.
Edraki N, Iraji A, Firuzi O, Fattahi Y, Mahdavi M, Foroumadi A, Khoshneviszadeh M, Shafiee A, Miri R. 2-Imino 2H-chromene and 2-(phenylimino) 2H-chromene 3-aryl carboxamide derivatives as novel cytotoxic agents: synthesis, biological assay, and molecular docking study. J. Iran. Chem. Soc. 2016;13:2163-71.
-
29.
Moosavi F, Ebadi A, Mohabbati M, Damghani T, Mortazavi M, Miri R, Firuzi O. Antiproliferative effect, alteration of cancer cell cycle progression and potential MET kinase inhibition induced by 3,4-dihydropyrimidin-2(1H)-one C5 amide derivatives. Eur. J. Pharmacol. 2021;894:173850. [PubMed ID: 33428899].
-
30.
Kumar NP, Nekkanti S, Kumari SS, Sharma P, Shankaraiah N. Design and synthesis of 1, 2, 3-triazolo-phenanthrene hybrids as cytotoxic agents. Bioorg. Med. Chem. Lett. 2017;27:2369-76. [PubMed ID: 28431881].
-
31.
Mohammadi MK, Firuzi O, Khoshneviszadeh M, Razzaghi-Asl N, Sepehri S, Miri R. Novel 9-(alkylthio)-Acenaphtho [1, 2-e]-1, 2, 4-triazine derivatives: synthesis, cytotoxic activity and molecular docking studies on B-cell lymphoma 2 (Bcl-2). DARU J. Pharm. Sci. 2014;22:2.
-
32.
Grozav A, Găină LI, Pileczki V, Crisan O, Silaghi-Dumitrescu L, Therrien B, Zaharia V, Berindan-Neagoe I. The synthesis and antiproliferative activities of new arylidene-hydrazinyl-thiazole derivatives. Int. J. Mol. Sci. 2014;15:22059-72. [PubMed ID: 25470024].
-
33.
Tripathi K, Rai A, Sonkar AK, Yashaswee S, Trigun SK, Mishra L. Synthesis, photo-physical, computational and invitro cytotoxic studies of 4-((E)-2-benzylidenehydrazinyl)benzonitrile derivatives. J. Photochem. Photobiol. A. 2019;375:299-307.
-
34.
Shekari F, Sadeghpour H, Javidnia K, Saso L, Nazari F, Firuzi O, Miri R. Cytotoxic and multidrug resistance reversal activities of novel 1, 4-dihydropyridines against human cancer cells. Eur. J. Pharmacol. 2015;746:233-44. [PubMed ID: 25445037].
-
35.
Menezes JC, Edraki N, Kamat SP, Khoshneviszadeh M, Kayani Z, Mirzaei HH, Miri R, Erfani N, Nejati M, Cavaleiro JA. Long chain alkyl esters of hydroxycinnamic acids as promising anticancer agents: selective induction of apoptosis in cancer cells. J. Agric. Food Chem. 2017;65:7228-39. [PubMed ID: 28718636].
-
36.
Qiu P, Zhang S, Zhou Y, Zhu M, Kang Y, Chen D, Wang J, Zhou P, Li W, Xu Q. Synthesis and evaluation of asymmetric curcuminoid analogs as potential anticancer agents that downregulate NF-κB activation and enhance the sensitivity of gastric cancer cell lines to irinotecan chemotherapy. Eur. J. Med. Chem. 2017;139:917-25. [PubMed ID: 28881286].
-
37.
Dai YL, Jiang YF, Lee HG, Jeon YJ, Kang MC. Characterization and screening of anti-tumor activity of fucoidan from acid-processed hijiki (Hizikia fusiforme). Int. J. Biol. Macromol. 2019;139:170-80. [PubMed ID: 31336117].
-
38.
Raji I, Yadudu F, Janeira E, Fathi S, Szymczak L, Kornacki JR, Komatsu K, Li JD, Mrksich M, Oyelere AK. Bifunctional conjugates with potent inhibitory activity towards cyclooxygenase and histone deacetylase. Bioorg. Med. Chem. 2017;25:1202-18. [PubMed ID: 28057407].
-
39.
Balachandran C, Haribabu J, Jeyalakshmi K, Bhuvanesh NSP, Karvembu R, Emi N, Awale S. Nickel(II) bis(isatin thiosemicarbazone) complexes induced apoptosis through mitochondrial signaling pathway and G0/G1 cell cycle arrest in IM-9 cells. J. Inorg. Biochem. 2018;182:208-21. [PubMed ID: 29510336].
-
40.
Phosri S, Jangpromma N, Chang LC, Tan GT, Wongwiwatthananukit S, Maijaroen S, Anwised P, Payoungkiattikun W, Klaynongsruang S. Siamese Crocodile White Blood Cell Extract Inhibits Cell Proliferation and Promotes Autophagy in Multiple Cancer Cell Lines. J. Microbiol. Biotechnol. 2018;28:1007-21. [PubMed ID: 29847866].
-
41.
Ge BC, Feng HF, Cheng YF, Wang HT, Xi BM, Yang XM, Xu JP, Zhou ZZ. Design, synthesis and biological evaluation of substituted aminopyridazin-3 (2H)-ones as G0/G1-phase arresting agents with apoptosis-inducing activities. Eur. J. Med. Chem. 2017;141:440-5. [PubMed ID: 29040954].
-
42.
Li E, Hu Z, Sun Y, Zhou Q, Yang B, Zhang Z, Cao W. Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance. Tumor. Biol. 2016;37:7843-52.
-
43.
Lu S, Török HP, Gallmeier E, Kolligs FT, Rizzani A, Arena S, Göke B, Gerbes AL, De Toni EN. Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1. Oncotarget. 2015;6:22167-78. [PubMed ID: 26259250].
-
44.
Damghani T, Sedghamiz T, Sharifi S, Pirhadi S. Critical c-Met-inhibitor interactions resolved from molecular dynamics simulations of different c-Met complexes. J. Mol. Struct. 2020;1203:127456.
-
45.
Parikh PK, Ghate MD. Recent advances in the discovery of small molecule c-Met Kinase inhibitors. Eur. J. Med. Chem. 2018;143:1103-38. [PubMed ID: 29157685].